What is the 13F Pro Quality Score for STEX?

13F Pro ranks Streamex Corp. (STEX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View STEX's current score at https://13fpro.ai/research/STEX (free sign-up required for the full ranking).

Where does 13F Pro source STEX data?

All Streamex Corp. fundamentals and ownership data come directly from SEC EDGAR. Streamex Corp. files with the SEC under CIK 1530766. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is STEX in?

Streamex Corp. (STEX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is STEX research updated on 13F Pro?

STEX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Streamex Corp.(STEX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1530766 STEX stock profile & AI dashboard →

13F Pro Quality Score

21.8/100

Rank #2,654 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

95.6/100

Profitability

0.1/100

Balance Sheet

3.8/100

Earnings Quality

30.0/100

Free Cash Flow

0.1/100

Institutional Flow

10.6/100

Revenue Scale

0.1/100

Dilution Risk

0.4/100

STEX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Streamex Corp. (STEX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STEX at 21.8/100 on a 32-signal composite quality model, placing it at rank #2,654 of 2,879 stocks — the bottom half of the AI-ranked universe. STEX scores in the top quartile across revenue growth (95.6). Areas of concern include profitability (0.1) and free cash flow (0.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Streamex Corp. reports net income of $-46.7M, free cash flow of $-10.2M. Top institutional holders of STEX by reported 13-F value include Legacy Wealth Managment, /ID, VANGUARD CAPITAL MANAGEMENT, Yorkville Advisors Global,, based on the most recent SEC filings. STEX trades on the Nasdaq exchange and files with the SEC under CIK 1530766. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STEX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Streamex Corp. directly from SEC EDGAR. Streamex Corp.'s 13F Pro composite quality score has ranged between 22 and 27 since 2026, currently 21.8 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-46.7M

Free Cash Flow

Q1 2026

$-10.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+122.2% YoY

$40.0KFY 2024

FY19 —FY22 $286.0KFY23 $18.0KFY24 $40.0K

Net Income

+64.4% YoY

$-10.3MFY 2024

FY19 $-34.1MFY22 $-27.1MFY23 $-29.0MFY24 $-10.3M

Operating Income

+54.9% YoY

$-12.9MFY 2024

FY19 $-34.6MFY22 $-27.3MFY23 $-28.5MFY24 $-12.9M

EPS (Diluted)

+81.0% YoY

$-0.38FY 2024

FY19 —FY22 $-0.26FY23 $-1.98FY24 $-0.38

Total Assets

-53.2% YoY

$842.0KFY 2024

FY19 $14.2MFY22 $4.1MFY23 $1.8MFY24 $842.0K

Op. Cash Flow

+72.5% YoY

$-4.8MFY 2024

FY19 $-15.5MFY22 $-21.7MFY23 $-17.3MFY24 $-4.8M

Metric	FY 2024	FY 2023	FY 2022	FY 2019	FY 2017	FY 2016
Revenue	$40.0K +122.2%	$18.0K -93.7%	$286.0K	—	—	—
Net Income	$-10.3M +64.4%	$-29.0M -7.4%	$-27.1M +20.6%	$-34.1M -168.2%	$-12.7M -9.6%	$-11.6M
Operating Income	$-12.9M +54.9%	$-28.5M -4.6%	$-27.3M +21.2%	$-34.6M -168.1%	$-12.9M -15.6%	$-11.2M
EPS (Diluted)	$-0.38 +81.0%	$-1.98 -649.0%	$-0.26	—	—	—
Total Assets	$842.0K -53.2%	$1.8M -56.3%	$4.1M -71.1%	$14.2M +736.1%	$1.7M +36.9%	$1.2M
Operating Cash Flow	$-4.8M +72.5%	$-17.3M +20.2%	$-21.7M -40.2%	$-15.5M -107.3%	$-7.5M -46.3%	$-5.1M

AI Insight: STEX Financial Trends

Streamex remains pre-revenue with accelerating losses; Q4 2025 saw a $424M net loss, likely driven by non-cash charges, while operating burn persists.

• Revenue remains at $0M across all eight quarters; company has not achieved meaningful commercial traction.

• Operating cash burn averaged $2.6M/quarter through Q3 2025, then spiked to $3M–$10M in Q4 2025 and Q1 2026.

• Q4 2025 net loss of $424M far exceeds operating loss of $42M, suggesting significant non-operating or non-cash charges.

⚠ Equity swung from negative to $159M by Q1 2026, indicating major capital raise or accounting adjustment—source and sustainability unclear.

⚠ Operating losses narrowed from $20M (Q2 2025) to $36M (Q1 2026), but negative cash flow worsened—misalignment suggests timing or working-capital dynamics.

AI Insight: STEX Ratio Trends

Streamex's profitability metrics have collapsed, with Q1 2026 ROE at -117.5% and trailing ROIC at -89.9%, signaling severe operational distress.

• ROA deteriorated from -47.8% in Q3 2025 to deeply negative levels by Q1 2026, indicating sustained net losses and asset inefficiency.

• TTM ROIC stands at -65.3%, reflecting persistent destruction of shareholder capital over the trailing twelve months.

⚠ Q1 2026 ROE of -117.5% is the worst reported; no sign of stabilization or path back to profitability evident in available data.

⚠ Complete absence of operating margin, NPM, and ROE data for 2024–Q4 2025 prevents assessment of when deterioration began or severity timeline.

Get alerted when STEX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Streamex Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of STEX

Legacy Wealth Managment, LLC/ID
$7.9M7,029,351 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.5M3,957,994 sh
Yorkville Advisors Global, LP
$4.2M3,750,000 sh
BlackRock, Inc.
$1.1M933,112 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.0M918,787 sh
MILLENNIUM MANAGEMENT LLC
$818.2K724,052 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$748.2K662,081 sh
Shay Capital LLC
$636.1K562,924 sh
MARSHALL WACE, LLP
$606.7K536,920 sh
VANGUARD FIDUCIARY TRUST CO
$482.6K427,108 sh

Fund	Value	Shares
Legacy Wealth Managment, LLC/ID	$7.9M	7,029,351
VANGUARD CAPITAL MANAGEMENT LLC	$4.5M	3,957,994
Yorkville Advisors Global, LP	$4.2M	3,750,000
BlackRock, Inc.	$1.1M	933,112
GEODE CAPITAL MANAGEMENT, LLC	$1.0M	918,787
MILLENNIUM MANAGEMENT LLC	$818.2K	724,052
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$748.2K	662,081
Shay Capital LLC	$636.1K	562,924
MARSHALL WACE, LLP	$606.7K	536,920
VANGUARD FIDUCIARY TRUST CO	$482.6K	427,108

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put STEX on your watchlist

Track score changes the day Streamex Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is STEX a good stock to buy?

13F Pro's AI-powered analysis of Streamex Corp. (STEX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for STEX are available on the STEX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own STEX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling STEX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Streamex Corp.'s investment landscape.